RxDoctor Payments Data

Kristina Broughton, APRN

Family · Corbin, KYNPI 1831655166

Payments from drug & device makers

$687in general payments, 2019–2025

Across 43 payments — averaging $15.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$351
  • Pfizer$108
  • Vertex$62
  • Indivior Inc.$56
  • Boehringer Ingelheim$28
  • Teva Pharmaceuticals USA, Inc.$25
  • plus $57 from 3 others

What the payments were for

  • Food & beverage$687100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie29$351
Pfizer2$108
Vertex3$62
Indivior Inc.3$56
Boehringer Ingelheim2$28
Teva Pharmaceuticals USA, Inc.1$25
Lilly USA, LLC1$20
AstraZeneca1$19
Pear Therapeutics (US), Inc.1$18

How this compares

$687 in reported general payments places this provider in the 55th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$11,155
Medicare patients
16
Services billed
133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide21$22,135
OzempicSemaglutide22$19,650
Combivent RespimatIpratropium/Albuterol Sulfate36$17,228
LinzessLinaclotide24$13,583
JardianceEmpagliflozin15$9,017
SymbicortBudesonide/Formoterol Fumarate12$2,758
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen108$2,479
Ventolin HfaAlbuterol Sulfate22$1,256
Gabapentin141$1,152
Albuterol Sulfate HfaAlbuterol Sulfate51$1,077
Ondansetron OdtOndansetron26$476
Diclofenac Sodium42$454
Naproxen15$429
Ropinirole Hcl58$373
Tizanidine Hcl23$275

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimCombivent Respimat, Jardiance$28$26,24451 claims
Lilly USA, LLCMounjaro, Olanzapine$20$22,25033 claims
AbbVieLinzess$351$13,58324 claims
AstraZenecaSymbicort$19$2,75812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,374 family providers in Kentucky.

Other family in Corbin

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →